Overview

Safety and Efficacy of Multiple Doses of Canakinumab (ACZ885) in Chronic Obstructive Pulmonary Disease (COPD) Patients

Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
Was to evaluate the safety, tolerability and efficacy of multiple doses of canakinumab (ACZ885) vs. placebo when administered via intravenous infusion (IV), on pulmonary function in patients with COPD
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Novartis
Treatments:
Antibodies, Monoclonal